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CERVICAL CANCER SCREENING PROGRAM IN THAILAND: 
ASSESSMENT OF SERVICE COVERAGE AND DETERMINANTS OF 
PROGRAM UPTAKE
Sirisamutr T, Butchon R, Putchong C, Praditsitthikorn N, Insrisawang L, Suksomboon N, 
Tantivess S, Teerawattnanon Y
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Nonthaburi, 
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OBJECTIVES: In Thailand two approaches for cervical cancer screening, namely Pap 
smear and visual inspection with acetic acid (VIA), are introduced in the public sector. 
This study aims to assess the service coverage and the factors associating with screen-
ing test seeking behavior in two provinces, namely Chiangmai and Nakon Si Tham-
marat. METHODS: A cross-sectional household survey was conducted in 2009 in the 
two study provinces, among women aged 30–60 years old. A total of 1600 women 
were randomly selected by stratiﬁ ed four-stage sampling. Of these, 1577 were inter-
viewed (98% respondent rate). Descriptive statistics and logistic regression were used 
in the data analysis. RESULTS: This study suggests that the coverage rates of cervical 
screening tests in the past 5 years were relatively high; 76% in Chiangmai and 70% 
in Nakon Si Thammarat. In both provinces, Pap smear was more commonly intro-
duced than the VIA around two to three times. The most common reasons for not 
seeking screening tests was “the absence of symptoms,” followed by “the lack of time” 
and “feeling shy toward health workers.” A multivariate logistic regression analysis 
indicates that supporting and impeding factors of the screening service seeking behav-
ior were signiﬁ cantly associated with screening test. Women with the following char-
acteristics were more likely to seek the tests than others: age 40–50 years, agriculture 
occupation, child-bearing experience, cervical cancer history in family member, and 
ever exposing to the information regarding cervical cancer and screening tests. Mean-
while, respondents who were less likely than others to seek the screening services 
included cigarette smokers. CONCLUSIONS: There were several factors associating 
with the service seeking practices among women in these settings. In order to increase 
the service uptake, it is suggested that extensive education program concerning cervical 
cancer and screenings should be provided with the aim to abolish the misunderstand-
ings and increase awareness among target population. 
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OBJECTIVES: This study aimed to assess clinical efﬁ cacy of three adjuvant chemo-
therapy regimens, namely 1) Mayo clinic regimen (5-ﬂ uorouracil and leucovorin, 5FU/
LV); 2) FOLFOX4 (oxaliplatin plus 5-FU/LV); and 3) oral capecitabine for treatment 
of patients with stage III colon cancer. METHODS: A systematic review of random-
ized controlled trials (RCTs), and meta-analysis of RCT of adjuvant chemotherapy 
for patients with stage III colon cancer were included by searching through the 
Medline and Cochrane databases. The clinical efﬁ cacy studies of three adjuvant che-
motherapy regimens on improving survival outcomes of patients with stage III colon 
cancer were included. Indirect or mixed-treatment comparison meta-analysis with ﬁ x 
effect model was applied to combine results of several studies. The meta-analysis was 
carried out using Bayesian approach and WinBUGS14 software program. The 
summary efﬁ cacy of adjuvant chemotherapy were presented as odds ratio (OR) and 
its 95% conﬁ dence interval (CI). To test the variation of study outcomes between 
studies, heterogeneity test was also applied. RESULTS: Total of 714 abstracts were 
reviewed and four eligible studies related to adjuvant chemotherapy for patients with 
stage III colon cancer were included in the meta-analysis. Two studies compared oral 
capectitabine with 5-FU/LV, while one study compared FOLFOX4 with 5-FU/LV. 
Indirect comparison was used to compare FOLFOX 4 and oral capecitabine. When 
compared to 5-FU/LV, FOLFOX4 and oral capecitabine could signiﬁ cantly reduce the 
risk of death by 23% (OR = 0.77, 95% CI = 0.68–0.86) and 16% (OR = 0.84, 95% 
CI = 0.72–0.98), respectively. Moreover, the OR of mortality among patients treated 
by oxaliplatin plus 5-FU/LV was 0.92 (95% CI = 0.76–1.11) compared to capecitabine. 
CONCLUSIONS: Of three regimens for patients with adjuvant chemotherapy stage 
III colon cancer, FOLFOX4 could signiﬁ cantly yield the longest patient survival, fol-
lowed by capecitabine and 5-FU/LV. However, FOLFOX4 did not signiﬁ cantly reduce 
mortality events compared with capecitabine. 
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QUALITY OF LIFE IN ADVANCED CANCER PATIENT—COMPARISON 
OF PATIENT-REPORTED OUTCOME (PRO) AND PROXIES ASSESSMENT
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OBJECTIVES: While Quality Of Life (QOL) in subjects suffering from advanced 
cancer patient has been studied using a variety of generic or speciﬁ c instruments, only 
very few studies have analyzed the agreement between patients and proxy ratings on 
patients’ QOL. The objective of this study was to compare PRO of quality of life and 
proxy assessment using EORTC QLQ PAL-15. METHODS: We administered the 
EORTC QLQ PAL-15 to 32 patients and their own family, nurse and doctor, respec-
tively as proxies of patient. The QLQ PAL-15 is a 15-item shortened version of the 
EORTC QLQ-C30 cancer-speciﬁ c health-related quality of life measure consisting of 
two functional scale (physical and emotional), seven symptom scale (fatigue, pain, 
nausea and vomiting, dyspnea, appetite loss, insomnia, constipation), and single-item 
scale to assess quality of life. The analyses focused on intraclass correlation coefﬁ cients 
(ICCs) to comparing the ICC 95% lower conﬁ dence interval with critical value 0.70 
and Pearson’s correlation coefﬁ cients. RESULTS: Agreement between patients and 
proxies on the scales was excellent for physical function (ICC = 0.889) and fatigue 
(ICC = 0.739). Emotional function, emesis, pain, appetite loss, constipation, constipa-
tion and quality of life scale was fair agreement (ICC range from 0.471 to 0.739). 
Dyspnea (ICC = 0.301) and insomnia (ICC = 0.097) was poor agreement between 
PRO and proxies assessment. There were higher correlation with family than other 
proxies with patient in emotional function (r = 0.791, P < 0.001), insomnia (r = 0.774, 
P < 0.001), nausea and vomiting (r = 0.646, P < 0.001), appetite loss (r = 0.638, P < 
0.001), dyspnonea (r = 0.402, P < 0.005). There were higher correlation with nurse 
than other proxies with patient in physical function (r = 0.791, P < 0.001) and con-
stipation (r = 0.540, P < 0.001). There were higher correlation with doctor than other 
proxies in pain(r = 0.494, P < 0.001), and fatigue (r = 0.406, P < 0.005). CONCLU-
SIONS: The agreement between PROs and proxies assessment in QOL assessment is 
different by symptom and function. Family caregiver were more agreement than nurse 
and doctor. We need to paid attention to proxy assessment more carefully. 
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DIAGNOSTIC ACCURACY OF HISTOLOGY IN DIFFERENTIATING 
BETWEEN SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL 
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OBJECTIVES: The importance of identifying non-small cell lung cancer (NSCLC) 
histological subtype has increased recently because of the need to target high cost 
therapeutic agents to the correct patient population. This systematic review was 
undertaken to examine the diagnostic accuracy of histology in differentiating between 
subtypes of NSCLC, speciﬁ cally the ability to differentiate squamous from non-
squamous histology. METHODS: A systematic literature search was undertaken to 
identify studies that evaluated the reproducibility of histologic diagnosis by patholo-
gists in their reporting of NSCLC subtypes. Studies were screened systematically using 
a priori deﬁ ned eligibility criteria. The National Health and Medical Research Council 
(NHMRC) diagnostic levels of evidence were applied, and quality assessed using the 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. Data were 
extracted and re-analyzed to permit comparison of agreement in non-squamous and 
squamous cell carcinoma via 2 × 2 tables. Pooled diagnostic performance measures 
including sensitivity, speciﬁ city, positive predictive value (PPV), negative predictive 
value (NPV) were calculated, with the PPV being considered the most relevant indica-
tor for the treating clinician. RESULTS: Out of 1480 articles identiﬁ ed through the 
literature search, seven were eligible for inclusion. The PPV of non-squamous histology 
was consistently high in each individual study with only a small amount of variation 
between studies. This resulted in a very high pooled PPV of 95.3% (94.0–96.3%) for 
the primary meta-analysis. CONCLUSIONS: The high individual and pooled PPV 
suggests that pathologists can reliably differentiate between non-squamous and squa-
mous NSCLC. This is important in guiding oncologist decision-making in choosing 
the most appropriate therapy for their patients. It is also signiﬁ cant from a purchaser 
perspective; because it will limit cost leakage from prescriptions mistakenly given 
outside the drugs approved indication (i.e., to the incorrect NSCLC patient group) 
due to misdiagnosis. 
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EARLY ALERT SYSTEMS FOR NEW PHARMACEUTICALS—DO THEY 
HAVE AN IMPACT ON PHARMACEUTICAL REIMBURSEMENT 
DECISIONS?: A CROSS-NATIONAL COMPARISON
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OBJECTIVES: With the successful incorporation of horizon scanning (HS) into HTA 
it has been postulated that HS of pharmaceuticals may inform pharmaceutical assess-
ment for public reimbursement in Australia. This paper intends to examine the role 
of HS for pharmaceuticals, the effect that HS may have had on the introduction of 
new drugs onto the health market, and assess whether HS for pharmaceuticals would 
improve access to new drugs in Australia and New Zealand. METHODS: The 
EuroScan database of HS agencies was searched for pharmaceuticals assessed in 2004 
by the National Horizon Scanning Centre (UK) and the Canadian Agency for Drugs 
and Technologies in Health. Time taken to licensing and  public reimbursement or 
access approval, if given, in the UK, Canada, Australia and New Zealand was ascer-
tained. RESULTS: Of 21 drugs identiﬁ ed by HS in 2004 by the NHSC, 11 received 
licensing approval and the National Institute for Health and Clinical Excellence has 
